GITR-binding antibodies

Details GITR-binding antibodies GITR-binding antibodies

2006-03-27

2010-10-12

Landsman, Robert (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387100, C530S387300, C530S388150, C530S388220, C424S130100

Reexamination Certificate

active

07812135

ABSTRACT:
The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4444878 (1984-04-01), Paulus
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4745055 (1988-05-01), Schenk et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5179017 (1993-01-01), Axel et al.
patent: 5225539 (1993-07-01), Winter
patent: 5304489 (1994-04-01), Rosen
patent: 5530101 (1996-06-01), Queen et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5589369 (1996-12-01), Seidman et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5837821 (1998-11-01), Wu
patent: 5849992 (1998-12-01), Meade et al.
patent: 5892019 (1999-04-01), Schlom et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6111090 (2000-08-01), Gorman et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6420140 (2002-07-01), Hori et al.
patent: 6458592 (2002-10-01), Jakobovits et al.
patent: 6476198 (2002-11-01), Kang
patent: 6503184 (2003-01-01), Ni et al.
patent: 6509173 (2003-01-01), Ni et al.
patent: 6689607 (2004-02-01), Ni et al.
patent: 7025962 (2006-04-01), Gorman et al.
patent: 2002/0103345 (2002-08-01), Zhu
patent: 2002/0150993 (2002-10-01), Ashkenazi et al.
patent: 2003/0133936 (2003-07-01), Byrne et al.
patent: 2003/0138426 (2003-07-01), Ni et al.
patent: 2003/0153499 (2003-08-01), Ni et al.
patent: 2004/0157786 (2004-08-01), Bissery
patent: 2005/0014224 (2005-01-01), Collins et al.
patent: 2005/0048054 (2005-03-01), Hanabuchi et al.
patent: 2005/0069983 (2005-03-01), Ashkenazi et al.
patent: 2005/0180971 (2005-08-01), Ashdown
patent: 2005/0202008 (2005-09-01), Williams et al.
patent: 2005/0238628 (2005-10-01), Blau
patent: 2006/0002932 (2006-01-01), Vieweg
patent: 2006/0051350 (2006-03-01), van Oosterhout et al.
patent: 2006/0057111 (2006-03-01), Hedlund et al.
patent: 2006/0099171 (2006-05-01), Tone et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0135756 (2006-06-01), Gorman et al.
patent: 2006/0141573 (2006-06-01), Ashkenazi et al.
patent: 2006/0281146 (2006-12-01), Bodary et al.
patent: 2007/0098719 (2007-05-01), Smith et al.
patent: 2007/0178093 (2007-08-01), Hanabuchi et al.
patent: 2007/0184444 (2007-08-01), Abbas et al.
patent: 2007/0185017 (2007-08-01), Aggarwal et al.
patent: 2008/0220000 (2008-09-01), Moore et al.
patent: 0 068 763 (1987-04-01), None
patent: 0 255 694 (1988-02-01), None
patent: 0 125 023 (1991-06-01), None
patent: 0 120 694 (1993-07-01), None
patent: 0 368 684 (1994-03-01), None
patent: 0 266 663 (1995-01-01), None
patent: 0 256 654 (1996-09-01), None
patent: 0920505 (1999-06-01), None
patent: 1196186 (2002-04-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 88/03559 (1988-05-01), None
patent: WO 88/03565 (1988-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 94/09817 (1994-05-01), None
patent: WO-98/24895 (1998-06-01), None
patent: WO-99/40196 (1999-08-01), None
patent: WO 00/06605 (2000-02-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 00/58499 (2000-10-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 02/02781 (2002-01-01), None
patent: WO-03/006058 (2003-01-01), None
patent: WO-03/009865 (2003-02-01), None
patent: WO-03/049758 (2003-06-01), None
patent: WO-2004/084942 (2004-10-01), None
patent: WO-2004/107618 (2004-12-01), None
patent: WO 2005/007190 (2005-01-01), None
patent: WO-2005/007190 (2005-01-01), None
patent: WO-2006/078911 (2006-07-01), None
patent: WO-2006/132272 (2006-12-01), None
patent: WO-2007/084775 (2007-07-01), None
patent: WO-2007/133822 (2007-11-01), None
Balint, Robert F. et al., “Antibody engineering by parsimonious mutagenesis,”Gene, vol. 137:109-118 (1993).
Davies, Julian et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology, vol. 2:169-179 (1996).
Holt, Lucy J. et al., “Domain antibodies: proteins for therapy,”Trends in Biotechnology, vol. 21(11):484-490 (2003).
Hwang, W.Y. et al., “Use of human germline genes in a CDR homology-based approach to antibody humanization,”Methods, vol. 36(1):35-42 (2005).
Imgenex, “Monoclonal Antibody GITR (Clone DTA-1) FITC Conjugate,” retrieved online at: http://www.imgenex.com/antibody—details.php?catalog=IMG-5920C (2007).
Kanamaru, Fumiko et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+Regulatory CD4+T Cells,”The Journal of Immunology, vol. 172:7306-7314 (2004).
Kohm, Adam P. et al., “Cutting Edge: Ligation of the Glucocorticoid-Induced TNF Receptor Enhances Autoreactive CD4+T Cell Activation and Experimental Autoimmune Encephalomyelitis,”The Journal of Immunology, vol. 172:4686-4690 (2004).
Little, M. et al., “Of mice and men: hybridoma and recombinant antibodies,”Immunol. Today, vol. 21(8):364-370 (2000).
McHugh, Rebecca S. et al., “CD4+CD25+Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,”Immunity, vol. 16:311-323 (2002).
Nocentini, Giuseppe et al., “A new member of the tumor necrosis factor
erve growth factor receptor family inhibits T cell receptor-induced apoptosis,”Proc. Natl. Acad. Sci. USA, vol. 94:6216-6221 (1997).
R&D Systems, “Monoclonal, Anti-human GITR/TNFRSF18 Antibody,” Catalog No. MAB689 (2002).
R&D Systems, “Monoclonal, Anti-mouse GITR/TNFRSF18 Antibody,” Catalog No. MAB5241 (2006).
Ronchetti, Simona et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,”Eur. J. Immunol., vol. 34:613-622 (2004).
Shimizu, Jun et al., “Stimulation of CD2530CD4+regulatory T cells through GITR breaks immunological self-tolerance,”Nature Immunology, vol. 3(2):135-142 (2002).
Stephens, Geoffrey L. et al., “Engagement of Glucocorticoid-Induced TNFR Family-Related Receptor on Effector T Cells by its Ligand Mediates Resistance to Suppression by CD4+CD25+T Cells,”The Journal of Immunology, vol. 173:5008-5020 (2004).
Tone, Masahide et al., “Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells,”PNAS, vol. 100(25):15059-15064 (2003).
Internation

Affiliated with

Also associated with

Rating

GITR-binding antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GITR-binding antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GITR-binding antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4155082